H3 Relaxin Protects Against Myocardial Injury in Experimental Diabetic Cardiomyopathy by Inhibiting Myocardial Apoptosis, Fibrosis and Inflammation | Zendy

Xiaohui Zhang | Zendy; Liya Pan | Zendy; Kelaier Yang | Zendy; Yu Fu | Zendy; Yue Liu | Zendy; Jinyu Chi | Zendy; Xin Zhang | Zendy; Siting Hong | Zendy; Xiao Ma | Zendy; Xinhua Yin | Zendy

Open Access

H3 Relaxin Protects Against Myocardial Injury in Experimental Diabetic Cardiomyopathy by Inhibiting Myocardial Apoptosis, Fibrosis and Inflammation

Author(s) -

Xiaohui Zhang,

Liya Pan,

Kelaier Yang,

Yu Fu,

Yue Liu,

Jinyu Chi,

Xin Zhang,

Siting Hong,

Xiao Ma,

Xinhua Yin

Publication year - 2017

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000481843

Subject(s) - relaxin , diabetic cardiomyopathy , inflammasome , medicine , fibrosis , cardiac fibrosis , endocrinology , inflammation , streptozotocin , myocardial fibrosis , apoptosis , cardiac function curve , diabetes mellitus , cardiomyopathy , heart failure , biology , receptor , biochemistry

Apoptosis, fibrosis and NLRP3 inflammasome activation are involved in the development of diabetic cardiomyopathy (DCM). Human recombinant relaxin-3 (H3 relaxin) is a novel bioactive peptide that inhibits cardiac injury; however, whether H3 relaxin prevents cardiac injury in rats with DCM and the underlying mechanisms are unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research